Hetlioz and Mucinex d drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Hetlioz (tasimelteon) and Mucinex d (guaifenesin; pseudoephedrine hydrochloride). Common drug interactions include pneumonia among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Hetlioz and Mucinex d. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Hetlioz?

Hetlioz has active ingredients of tasimelteon. eHealthMe is studying from 7,418 Hetlioz users. Check the latest studies of Hetlioz.

What is Mucinex d?

Mucinex d has active ingredients of guaifenesin; pseudoephedrine hydrochloride. It is often used in sinus congestion. eHealthMe is studying from 1,926 Mucinex d users. Check the latest studies of Mucinex d.



On Jul, 13, 2026

12 people who take Hetlioz and Mucinex d together, and have interactions are studied.

Hetlioz and Mucinex d drug interactions.

What are the common drug interactions of Hetlioz and Mucinex D, by gender? *:

female:

  1. Pneumonia
  2. Malaise (a feeling of general discomfort or uneasiness)
  3. Respiratory disorder (respiratory disease)
  4. Upper respiratory tract infection
  5. Insomnia (sleeplessness)
  6. Somnolence (a state of near-sleep, a strong desire for sleep)
  7. Respiratory distress (difficulty in breathing)

male:

  1. Drug ineffective
  2. Nasopharyngitis (inflammation of the nasopharynx)

What are the common drug interactions of Hetlioz and Mucinex D, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Drug ineffective
  2. Nasopharyngitis (inflammation of the nasopharynx)

50-59:

  1. Pneumonia
  2. Malaise (a feeling of general discomfort or uneasiness)
  3. Respiratory disorder (respiratory disease)
  4. Upper respiratory tract infection
  5. Insomnia (sleeplessness)
  6. Respiratory distress (difficulty in breathing)
  7. Somnolence (a state of near-sleep, a strong desire for sleep)

60+:

n/a

What are the existing conditions these people have? *

  1. Circadian Rhythm Sleep Disorder (family of sleep disorders affecting, among other things, the timing of sleep): 7 people, 58.33%
  2. Blindness: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Hetlioz and Mucinex d?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Hetlioz and Mucinex d:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Hetlioz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Mucinex d:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Hetlioz and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Mucinex d and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on tasimelteon and guaifenesin; pseudoephedrine hydrochloride (the active ingredients of Hetlioz and Mucinex d, respectively), and Hetlioz and Mucinex d (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: